Close Menu
    Tripoli WireTripoli Wire
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Tripoli WireTripoli Wire
    Home » WHO and ECDC predict another COVID wave in Europe
    Health

    WHO and ECDC predict another COVID wave in Europe

    October 13, 2022
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    A new wave of COVID-19 infections may have begun in Europe as cases continue to rise, according to the World Health Organization and European Centre for Disease Prevention and Control (ECDC). “Even though we are not where we were one year ago, we still have a long way to go to contain the COVID-19 pandemic,” said Hans Kluge, WHO’s Europe director, and Andrea Ammon, ECDC’s director, in a joint statement.

    WHO and ECDC predict another COVID wave in Europe“We are unfortunately seeing indicators rise again in Europe, indicating that another wave of infections has begun.” According to WHO data, only Europe recorded an increase in COVID-19 cases in the week ended 2 October, up 8%. There are millions of people in Europe who have not been vaccinated against COVID-19, according to the WHO and ECDC. Experts warn that vaccine fatigue and confusion over available vaccines will likely limit booster uptake in the region.

    Related Posts

    WHO maps three-month path for Congo Ebola containment

    August 19, 2026

    DRC malaria cases surpass 26 million in 2025

    August 17, 2026

    DR Congo Ebola death toll tops 1,900 as cases rise

    August 11, 2026

    Obesity linked to 8.2% of Belgium deaths in new health report

    August 8, 2026

    Moderna begins Ebola vaccine trial amid DR Congo outbreak

    August 5, 2026

    Michigan reports first deaths tied to cyclospora outbreak

    August 4, 2026
    Latest News

    Wall Street rises after Treasury expands debt buybacks

    August 20, 2026

    Healthcare shares strengthen market gains
    Healthcare stocks provided another source of support during Wednesday’s session as several pharmaceutical shares recorded large gains. Moderna shares surged 177%, while Merck advanced 12.6% after the companies announced positive results from a Phase 3 melanoma trial. The INTerpath-001 study tested personalized mRNA therapy intismeran autogene with Keytruda following surgical removal of high-risk melanoma. The combination met its primary endpoint for recurrence-free survival. It also met a key secondary endpoint measuring survival without distant cancer spread.

    WHO maps three-month path for Congo Ebola containment

    August 19, 2026

    Indonesia 6.1 earthquake rattles North Sumatra coast

    August 19, 2026

    DRC Ebola outbreak sets national death toll record

    August 17, 2026

    DRC malaria cases surpass 26 million in 2025

    August 17, 2026

    South Korea auto exports reach $6.24 billion in July

    August 14, 2026

    Total solar eclipse crosses Russian Arctic and Europe

    August 13, 2026

    International Youth Day 2026 puts youth inclusion in focus

    August 13, 2026
    © 2026 Tripoli Wire | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.